Suven Life Sciences said it has received two product patents for its new chemical entities (NCEs) used in treating disorders like Alzheimer's disease,Parkinson and Schizophrenia. The company has received patents by the Indian Patent Office which are valid till 2027,Suven said in a filing to the Bombay Stock Exchange (BSE). "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS area that are being developed for cognitive disorders which has an estimated USD 30 billion market potential globally",Suven CEO Venkat Jasti said. Products of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II,the company said in a statement. With these new patents,Suven has a total of 11 granted Indian patents on new chemical entities. Shares of Suven today closed at Rs 24.8 on the National Stock Exchange (NSE),up 2.48 per cent from its previous close.
